Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

Table 3

ARI severity (according to AUC of TSSS for days 2–6).

	Group		Statistics
	Ergoferon (n = 140)	Placebo (n = 142)
AUC (TSSS × n), dayscore
Mean ± SD [95% CI]	39.6 ± 18.8 [36.4–42.8]	44.6 ± 20.6 [41.2–48.1]	Z = 2.00
Median	38.5	43.1
Q1–Q3	24.3–52.0	28.5–58.0

Notes.The statistics column shows the results of the Wilcoxon test; the Shapiro–Wilk test confirmed abnormal distribution of data (Ergoferon, ; placebo, ). SD: standard deviation; СI: confidence interval; Q1–Q3: boundaries of the 1^st and 3^rd quartiles.